

IMPACT OF SARS-COV-2 INFECTION IN ACUTE MYELOID LEUKAEMIA PATIENTS: EXPERIENCE OF THE PETHEMA REGISTRY

Palanques T, Megías J, Martínez P, Cornago J, López JL, Rodríguez G, Cano I, Arnan M, Poveda JL, Montesinos P.  CONTACT DATA: palanques_tom@gva.es

BACKGROUND AND IMPORTANCE

SARS-CoV-2 infection impact survival of patients with AML, but there is little evidence in AML

AIM AND OBJECTIVES

To analyze the clinical futures and outcome of SARS-CoV-2 infection in AML patients

MATERIAL AND METHODS

- ✓ Observational study with 117 patients reported from 47 Spanish centers (March – May 2020)
- ✓ Leukemic and viral affections were studied and interrelationships were established

RESULTS

BASELINE CHARACTERISTICS	
Age (mean)	68 years
Sex (male)	56.7%
Time AML-COVID-19 (mean)	4 months
Comorbidities (mean)	1.2
Cytogenetic risk	
• Low	16.9%
• Intermediate	57.1%
• High	26.0%
AML status	
• Active disease	55.7%
• Complete remission	39.2%
• Partial response	5.1%
AML treatment	70.6%
Treatment lines	
• New diagnosed	3.7%
• One	77.8%
• Two	14.8%
• Four	3.7%
Allogeneic trasplantation	15.4%

INFECTION CHARACTERISTICS	
COVID-19 symptoms	96.0%
• Fever	77.8%
• Pneumonia	75.0%
• Cough	65.3%
• Dyspnea	52.0%
• Diarrhea	20.4%
COVID-19 treatment	84.2%
COVID-19 course	
• Mild	14.7%
• Moderate	32.0%
• Severe	53.3%
Time negativization (mean)	20.5 days
Duration symptoms (mean)	17.6 days
Hospital stay (mean)	11.1 days
AML treatment	
• Maintained	48.1%
• Delayed	26.6%
• Modified	25.3%
Patients died	47.5%

ASSOCIATION BETWEEN MORTALITY AND:

- **> 60 years** (58.3%vs36.4%,p=0.043)
- **≥2 AML treatment** (72.7%vs44.3%,p=0.020)
- **Active disease** (62.5%vs29.4%,p=0.002)
- **Pneumonia** (61.2%vs22.7%,p=0.002)

CONCLUSIONS AND RELEVANCE

- SARS-CoV-2 infection produces high mortality among AML patients
- Mortality was correlated with age, lines of treatment, active disease and pneumonia

ACKNOWLEDGEMENTS: PETHEMA foundation